Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: are the available data convincing?

Non-small cell lung cancer (NSCLC) represents the leading cause of death for cancer (1). In 2004, for the first time Lynch et al. demonstrated that a subgroup of NSCLC patients (10–15%), harboring somatic mutations in the epidermal growth factor receptor (EGFR) gene, showed sensitivity and clinical benefit to a novel class of drugs targeting the tyrosine kinase domain; the so called tyrosine kinase inhibitors (TKIs) (2).